KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Receivables (2016 - 2025)

Historic Receivables for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.9 billion.

  • Vertex Pharmaceuticals' Receivables rose 1118.47% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 1118.47%. This contributed to the annual value of $1.6 billion for FY2024, which is 294.23% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Receivables of $1.9 billion as of Q3 2025, which was up 1118.47% from $1.9 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' Receivables' 5-year high stood at $1.9 billion during Q3 2025, with a 5-year trough of $929.1 million in Q2 2021.
  • Over the past 5 years, Vertex Pharmaceuticals' median Receivables value was $1.5 billion (recorded in 2023), while the average stood at $1.5 billion.
  • In the last 5 years, Vertex Pharmaceuticals' Receivables soared by 4345.49% in 2022 and then surged by 66.36% in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Receivables (Quarter) stood at $1.1 billion in 2021, then grew by 26.86% to $1.4 billion in 2022, then increased by 8.4% to $1.6 billion in 2023, then rose by 2.94% to $1.6 billion in 2024, then increased by 20.94% to $1.9 billion in 2025.
  • Its last three reported values are $1.9 billion in Q3 2025, $1.9 billion for Q2 2025, and $1.8 billion during Q1 2025.